CST3 and acute kidney injury: The biomarker model had comparable performance at earlier timepoints of Day 30 and 60.<h4>Conclusions</h4>A biomarker panel comprising sTNFR1, sTNFR2, cystatin C and eGFR reliably predicts adverse outcomes up to 1 year post-AKI.